Verrica Pharmaceuticals (VRCA) Change in Account Payables (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Change in Account Payables of $121000.0 for Q1 2026, up 126.71% year-over-year from $53372.0 in Q1 2025, and down 75.15% quarter-over-quarter from $487000.0 in Q4 2025.
Verrica Pharmaceuticals (VRCA) Change in Account Payables (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Change in Account Payables history runs 10 years deep, the most recent figure standing at $121000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables rose 126.71% year-over-year to $121000.0; the TTM figure through Mar 2026 stood at $750000.0 (up 169.9% YoY), while the FY2025 annual figure was $176000.0, up 130.99% from the prior year.
- Change in Account Payables for Q1 2026 stood at $121000.0, down from $487000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $1.5 million in Q2 2023, with the low at -$1.4 million in Q2 2024.
- The 5-year median for Change in Account Payables is $121000.0 (2023), against an average of $93647.1.
- The sharpest annual moves came in 2022 and 2025: Change in Account Payables jumped 1580.0% in 2022, then tumbled 971.15% in 2025.
- Verrica Pharmaceuticals' Change in Account Payables stood at $370000.0 in 2022, then jumped by 56.22% to $578000.0 in 2023, then surged by 61.07% to $931000.0 in 2024, then plunged by 47.69% to $487000.0 in 2025, then plunged by 75.15% to $121000.0 in 2026.
- Business Quant data shows VRCA's Change in Account Payables at $121000.0 in Q1 2026, $487000.0 in Q4 2025, and -$736000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | -590,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -590,000.00 |
| Jun 30, 2026 | -590,000.00 |
| Mar 31, 2026 | 121,000.00 |
| Mar 31, 2026 | 121,000.00 |
| Dec 31, 2025 | 487,000.00 |
| Dec 31, 2025 | 487,000.00 |
| Sep 30, 2025 | -736,000.00 |
| Sep 30, 2025 | -736,000.00 |
| Jun 30, 2025 | 878,000.00 |
| Jun 30, 2025 | 878,000.00 |
| Mar 31, 2025 | -453,000.00 |
| Mar 31, 2025 | -453,000.00 |
| Dec 31, 2024 | 931,000.00 |
| Dec 31, 2024 | 931,000.00 |
| Sep 30, 2024 | -169,000.00 |
| Sep 30, 2024 | -169,000.00 |
| Jun 30, 2024 | -1.38 Mn |
| Jun 30, 2024 | -1.38 Mn |
| Mar 31, 2024 | 52,000.00 |
| Mar 31, 2024 | 52,000.00 |